ClinicalTrials.gg
CompletedNCT03677154Updated Aug 21, 2025

Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma

A Phase 1/2 interventional study of Mosunetuzumab Intravenous (IV) and Mosunetuzumab Subcutaneous (SC) in Diffuse Large B-cell Lymphoma, sponsored by Hoffmann-La Roche. Completed at 32 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-21.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
188
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse — 15 open to participants now, 18 under way, 1 of them phase 3. polatuzumab vedotin · Lymphoma, Large B-Cell, Diffuse.

Enrollment
6th of 28
188 · median 42
Started
2019
the only one that year
Phase 1/2
4 of 28
1 open now
Registered
3rd of 28
by date
Lead sponsor
6 of 28
Hoffmann-La Roche

Among the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse, this one is the 6th largest by enrollment, is the only one that started in 2019, is one of 4 in phase 1/2, and was the 3rd registered.

Lymphoma, Large B-Cell, Diffuse

1,872 studies on the registry are indexed under Lymphoma, Large B-Cell, Diffuse; 359 are open to participants now.

Browse Lymphoma, Large B-Cell, Diffuse studies →

Open to participants now

15 of the 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse are open now, in 2 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

About polatuzumab vedotin

polatuzumab vedotin: first FDA approval 2019 (POLIVY), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 266 Lymphoma, Large B-Cell, Diffuse studies recruiting now, 177 (67%) set no upper age limit and 51 (19%) stop at 75 or younger; 25 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies testing polatuzumab vedotin in Lymphoma, Large B-Cell, Diffuse, or all of them as a file.
02

Study summary

This study will evaluate the safety, pharmacokinetics, and preliminary efficacy of mosunetuzumab following first-line diffuse large B-cell lymphoma (DLBCL) immunochemotherapy in participants with a best response of stable disease or partial response, or in elderly/unfit participants with previously untreated DLBCL, or subcutaneous mosunetuzumab in combination with polatuzumab vedotin IV in elderly/unfit participants with previously untreated DLBCL.

03

Conditions studied

  • Diffuse Large B-cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria for All Cohorts

  • At least one bi-dimensionally measurable nodal lesion, defined as > 1.5 cm in its longest dimension, or one bi-dimensionally measurable extranodal lesion, defined as > 1.0 cm in its longest diameter
  • Adequate hematologic function
  • (ECOG) Performance Status of 0, 1, or 2; with the exception of South Korea, where participants 80 years or older with ECOG >/= 2 will not be eligible

Inclusion Criteria Specific to Cohort A

Participants in Cohort A must also meet the following criteria for study entry:

  • confirmed DLBCL according to World Health Organization (WHO) 2016 expected to express the cluster of differentiation-20 (CD20) antigen
  • One prior therapy with any systemic anthracycline-based chemoimmunotherapy containing regimen for previously untreated DLBCL
  • Best response of SD or PR to prior systemic chemoimmunotherapy at the end of induction treatment in accordance with the Lugano 2014 criteria

Inclusion Criteria Specific to Cohorts B and C

Participants in Cohorts B and C must also meet the following criteria for study entry:

  • Previously untreated, histologically confirmed, DLBCL according to WHO 2016 classification
  • Age >/= 80 years, or
  • Age 65-79 years and considered ineligible for chemoimmuotherapy (R-CHOP) with at least one of the following: Impairment in at least two activity of daily living (ADL) components as defined in the protocol; impairment in at least two instrumental ADL components as defined in the protocol; cumulative illness rating scale - geriactic (CIRS-G) score of at least one cormorbidity with a severity score of 3-4 (not including lymphoma and hematologic deficiencies due to lymphoma) or a score of 2 in >/= 8 comorbidities; impairment in cardiac function, renal function, liver function, or other comorbidities such that the participant is unfit for full-dose immunochemotherapy, such as rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP)
  • Participants with an initial ECOG performance status of 3 may be considered during screening if the performance status is DLBCL-related and if pre-phase treatment during the screening phase (not more than 100 mg/day up to 7 days prior to Cycle 1 Day 1) results in an improvement of ECOG performance status to \</= 2 prior to enrollment

Exclusion Criteria for All Cohorts

Participants who meet any of the following criteria will be excluded from study entry:

  • Transformed lymphoma
  • CNS lymphoma
  • Prior treatment with mosunetuzumab
  • Prior stem cell transplant (autologous and allogeneic)
  • History of confirmed progressive multifocal leukoencephalopathy (PML)
  • Known or suspected chronic active Epstein Barr virus (CAEBV), , (HCV), or (HIV)
  • Known or suspected history of hemophagocytic lymphohistiocytosis (HLH)
  • Positive SARS-CoV-2 antigen or PCR test within 30 days prior to Cycle 1 Day 1
  • Prior solid organ transplantation
  • Current or past history of central nervous system (CNS) disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease
  • history of liver disease
  • Prior treatment with radiotherapy within 2 weeks prior to Cycle 1, Day 1 (C1D1)
  • Significant cardiovascular disease

Exclusion Criteria Specific to Cohort A

Participants in Cohort A who meet the following criteria will be excluded from study entry:

- Prior anti-lymphoma treatment with chemotherapy, immunotherapy, or biologic therapy 4 weeks prior to C1D1

Exclusion Criterion Specific to Cohorts B and C

Participants in Cohorts B and C who meet the following criterion will be excluded from study entry:

- Prior treatment for DLBCL with chemotherapy, immunotherapy, and biologic therapy

Exclusion Criteria Specific to Cohort C

Participants in Cohort C who meet the following criteria will be excluded from study entry:

- Current Grade >1 peripheral neuropathy by clinical examination or demyelinating form of Charcot-Marie-Tooth disease

Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
188 participants (actual)

Study arms

  • Experimental
    Consolidation Therapy (Cohort A)

    Participants with a partial response to first-line chemotherapy will receive mosunetuzumab up to the recommended consolidation dose (RCD).

    Drug: Mosunetuzumab Intravenous (IV) · Drug: Tocilizumab

  • Experimental
    Elderly/Unfit Previously Untreated Monotherapy (Cohort B)

    Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab at the previously determined recommended phase II dose (RP2D).

    Drug: Mosunetuzumab Intravenous (IV) · Drug: Tocilizumab

  • Experimental
    Elderly/Unfit Previously Untreated Combination Therapy (Cohort C)

    Elderly/unfit participants with previously untreated DLBCL will receive mosunetuzumab in combination with polatuzumab vedotin.

    Drug: Mosunetuzumab Subcutaneous (SC) · Drug: Polatuzumab Vedotin · Drug: Tocilizumab

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Adverse Events

    Time frame: Baseline through approximately 90 days after last study treatment

  2. Positron Emission Tomography-Computed Tomography (PET-CT) Complete Response (CR) Rate at Time of Primary Response Assessment (PRA) According to Lugano 2014 Response Criteria (Cohort A)

    Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)

  3. PET-CT Objective Response Rate (ORR) at PRA According to Lugano 2014 Response Criteria as Determined by the Investigator (Cohort B)

    Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)

  4. PET-CT ORR at PRA According to the Lugano 2014 Criteria as Determined by an Independent Review Committee (IRC) (Cohort C)

    Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)

Secondary outcomes

  1. Maximum Serum Concentration (Cmax) of Mosunetuzumab IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  2. Minimum Serum Concentration (Cmin) of Mosunetuzumab IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  3. Area Under the Curve (AUC) of Mosunetuzumab IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  4. Clearance (CL) of Mosunetuzumab IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  5. Volume of Distribution at Steady State (Vss) of Mosunetuzumab IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  6. Maximum Serum Concentration (Cmax) of Mosunetuzumab SC

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  7. Time to Maximum Serum Concentration (Tmax) of Mosunetuzumab SC

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  8. Minimum Serum Concentration (Cmin) of Mosunetuzumab SC

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  9. Area Under the Curve (AUC) of Mosunetuzumab SC

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  10. Clearance (CL) of Mosunetuzumab SC

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  11. Volume of Distribution at Steady State (Vss) of Mosunetuzumab SC

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  12. Maximum Serum Concentration (Cmax) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  13. Minimum Serum Concentration (Cmin) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  14. Area Under the Curve (AUC) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  15. Clearance (CL) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  16. Volume of Distribution at Steady State (Vss) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  17. End of Infusion Concentration (Ceoi) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  18. Trough Concentration (Ctrough) of Polatuzumab Vedotin IV

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  19. PET-CT Rate According to the Lugano 2014 Criteria at PRA as Determined by the Investigator (Cohorts B and C) and IRC (Cohort C)

    Time frame: 6-8 weeks after Cycle 8 Day 1 or the final dose of study treatment (cycle = 21 days)

  20. Objective Response Rate (ORR), Defined as the Proportion of Participants with a Complete Response (CR) or Partial Response (PR) at PRA as Determined by the Investigator (Cohorts A and C)

    Time frame: Baseline through 2 years after PRA (up to a total of approximately 2.5 years)

  21. Best ORR (CR or PR at any time) During the Study Based on PET-CT and/or CT Scans as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)

    Time frame: Baseline through 2 years after PRA (up to a total of approximately 2.5 years)

  22. Duration of Response (DOR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)

    Time frame: From the first occurrence of a documented objective response to disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)

  23. Duration of Confirmed Response (DOCR) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)

    Time frame: From the first occurrence of a documented CR to disease progression or relapse, or death from any cause, whichever occurs first (up to approximately 2.5 years)

  24. Progression-Free Survival (PFS) as Determined by the Investigator (All Cohorts) and by IRC (Cohort C)

    Time frame: From the first study treatment to the first occurrence of disease progression, relapse, or death, whichever occurs first (up to approximately 2.5 years)

  25. Overall Survival (OS)

    Time frame: From the first study treatment to death from any cause

  26. Time to Deterioration in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Physical Functioning and Fatigue (Cohorts B and C)

    Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)

  27. Time to Deterioration in European Organization for Research and Treatment of Cancer Item Library (EORTC-IL17) Physical Functioning (Cohorts B and C)

    Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)

  28. Time to Deterioration in the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) Subscale (Cohorts B and C)

    Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)

  29. Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC QLQ-C30 (Cohorts B and C)

    Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)

  30. Proportion of Participants Achieving a Clinically Meaningful Improvement in Physical Functioning as Measured by EORTC IL17 (Cohorts B and C)

    Time frame: From the first study treatment to the first occurrence of disease progression, relapse, initiation of new anti-lymphoma treatment, or death from any cause, whichever occurs first (up to approximately 2.5 years)

  31. Anti-Drug Antibodies (ADAs) to Mosunetuzumab

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

  32. Anti-Drug Antibodies (ADAs) to Polatuzumab Vedotin (Cohort C)

    Time frame: At pre-defined intervals from Cycle 1 Day 1 through approximately 90 days after the last study treatment (cycle = 21 days)

07

Study locations

32 sites
  • University of Alabama at Birmingham School of Medicine
    Birmingham, Alabama 352331912, United States
  • University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica
    Santa Monica, California 90404-2023, United States
  • Fort Wayne Medical Institute
    Fort Wayne, Indiana 46805, United States
  • University of Maryland Medical Center
    Baltimore, Maryland 21201, United States
  • Duke University
    Durham, North Carolina 27708-9963, United States
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
  • Rhode Island Hospital
    Providence, Rhode Island 02903, United States
  • Texas Oncology - Baylor Charles A. Sammons Cancer Center
    Dallas, Texas 75246, United States
  • Soroka Medical Center
    Beersheba, 8410101, Israel
  • Rambam Medical Center
    Haifa, 31096, Israel
  • Carmel medical center
    Haifa, 3436212, Israel
  • Shaare Zedek Medical Center
    Jerusalem, 9103102, Israel
  • Hadassah Ein-Karem
    Jerusalem, 91120, Israel
  • Meir Medical Center
    Kfar Saba, 4428164, Israel
  • Sheba Medical Center
    Ramat Gan, 5262100, Israel
  • Uniwersyteckie Centrum Kliniczne
    Gdansk, 80-214, Poland
  • PRATIA MCM Kraków
    Krakow, 30-727, Poland
  • Centrum Onkologii Ziemi Lubelskiej im. ?w. Jana z Dukli
    Lublin, 20-090, Poland
  • Szpital Wojewodzki w Opolu
    Opole, 45-372, Poland
  • Pusan National University Hospital
    Busan, 49241, South Korea
  • Keimyung University Dongsan Hospital
    Daegu, 41931, South Korea
  • Samsung Medical Center
    Seoul, (0)6351, South Korea
  • The Catholic University of Korea Yeouido St. Mary's Hospital
    Seoul, (0)7345, South Korea
  • Seoul National University Hospital
    Seoul, 03080, South Korea
  • Severance Hospital, Yonsei University
    Seoul, 03722, South Korea
  • Hospital Universitario Virgen Macarena
    Seville, Sevilla 41071, Spain
  • Hospital Universitario Vall d Hebron
    Barcelona, 08035, Spain
  • Institut Catala d Oncologia Hospitalet
    Barcelona, 08908, Spain
  • Hospital San Pedro de Alcantara
    Cáceres, 10003, Spain
  • Hospital General Universitario Gregorio Marañon
    Madrid, 28007, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • National Taiwan University Hospital
    Taipei, 10002, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Aug 2025, 74 months.

Of 51 industry-sponsored phase 1/2 interventional studies under Lymphoma, Large B-Cell, Diffuse, half reached primary completion within 75 months of starting (the median), counting those still running; a quarter within 54 and three quarters within 99. This study's 74 months is close to that.

Counting every sponsor, half of 108 studies reached it within 70 months; a quarter within 50 and three quarters within 98.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 11, 2018
First posted
Sep 19, 2018
StartActual
May 23, 2019
Primary completionActual
Aug 7, 2025
CompletionActual
Aug 7, 2025
Last update
Aug 21, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03677154
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 19, 2018
Start date
May 23, 2019
Primary completion
Aug 7, 2025
Completion
Aug 7, 2025
Last update
Aug 21, 2025

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mosunetuzumab · Polatuzumab vedotin

Start the discussion